Breast Cancer Treatment & Medicine Options — Personalised for Your Tumour

The most common subtype. Cells carry receptors that oestrogen "feeds". The main drug therapy is hormone-blocking therapy — daily tablets that reduce oestrogen signalling. This is the first-line treatment for most early-stage ER/PR-positive breast cancers. Treatment typically continues for five to ten years. For advanced or high-risk cases, additional therapies that block the cell-division cycle may be added alongside hormone-blocking therapy.

Cells overproduce the HER2 protein, which drives rapid growth. The first-line treatment includes targeted antibody therapy that attaches to the HER2 protein and blocks it — given together with chemotherapy. This is most commonly given before surgery (neoadjuvant) to shrink the tumour first. Biological treatment for breast cancer has transformed HER2-positive outcomes. Patients who achieve a complete tumour response before surgery have significantly better long-term outcomes; your oncologist will review whether dual HER2-targeted therapy is appropriate for your case.

Negative for ER, PR, and HER2 — so hormone-blocking and HER2-targeted therapies do not apply. Chemotherapy is the core first-line drug therapy, often given before surgery. For eligible patients, immunotherapy alongside chemotherapy improves the rate of complete tumour response. BRCA gene testing is recommended for all TNBC patients, as a positive result opens additional treatment options. When complete response is achieved, long-term outcomes can be very good.

Some tumours carry all three positive markers. These receive a combination approach: targeted antibody therapy for HER2 alongside chemotherapy (often neoadjuvant), followed after surgery by hormone-blocking therapy for long-term maintenance. The tumor board reviews both components together to avoid overlap and sequence treatments correctly for the best outcome.

When breast cancer has spread to other organs, the goal of treatment shifts to managing the disease for as long as possible while preserving quality of life. ER/PR-positive metastatic breast cancer is often controlled for years with hormone-blocking therapy combined with cycle-blocking agents. HER2-positive metastatic disease responds well to continued targeted antibody therapy. A CION medical oncologist will explain the realistic goals of each option honestly, in plain language.

The receptor profile is the single most important factor in selecting drug therapy for breast cancer. ER and PR positivity points toward hormone-blocking therapy as the backbone of treatment. HER2 positivity means targeted antibody therapy must be part of the plan. Ki-67, a measure of how fast the tumour is dividing, helps the board decide how aggressive the chemotherapy component needs to be. Without this full receptor panel, it is not possible to choose the right first-line treatment — which is why CION reviews every biopsy before the consultation, not during it.

Stage determines the sequence of treatment. For most early-stage cancers, surgery comes first. For larger tumours (Stage II or III), or for HER2-positive and triple-negative cancers at any stage, starting with drug therapy before surgery (neoadjuvant treatment) is often the better approach. Neoadjuvant treatment can shrink a tumour enough to allow breast-conserving surgery where mastectomy would otherwise have been necessary, and it provides a real-time measure of how well the chosen medicines are working. The decision between surgery-first and drug-therapy-first is reviewed case by case.

A BRCA1 or BRCA2 mutation — detected by a simple blood or saliva test — affects the surgical recommendation (many BRCA carriers choose preventive mastectomy of the other breast), the drug therapy plan (BRCA-positive patients are eligible for a class of DNA-repair inhibitor medicines after primary treatment), and the recommendation to test first-degree family members. At CION, BRCA testing is discussed with all patients diagnosed under 45, all triple-negative breast cancer patients, and any patient with a relevant family history. The result is reviewed with genetic counselling to help you and your family understand what it means.

Hormone-blocking therapy works differently in premenopausal and postmenopausal women — the medicines used and their duration differ. For women who wish to have children after treatment, the tumor board includes a discussion about fertility preservation options before chemotherapy begins. Egg or embryo freezing before chemotherapy is a well-established option that does not delay treatment significantly. Young women with breast cancer also have a higher rate of hereditary disease, making BRCA testing particularly important in this group.

Some chemotherapy regimens affect the heart — which matters if a patient has pre-existing cardiac disease. Some hormone-blocking therapies affect bone density — which matters if osteoporosis is already present. Your tumor board reviews your complete health history and other medications before recommending any regimen. In elderly patients or those with significant comorbidities, the board will sometimes recommend a less intensive but still effective plan that achieves the treatment goal without unacceptable side effects. Decisions for healing, not billing — that means recommending only what genuinely benefits you.

The right treatment plan is one you can actually follow — practically and financially. CION discusses cost openly: indicative cost ranges are provided in writing before any treatment starts. Insurance (cashless where available), Aarogyasri, CGHS, ECHS, and EMI payment plans are available. Some patients prefer a hospital closer to home; our 35+ centres across Telangana and Andhra Pradesh mean most patients can receive infusion therapy or follow-up close to where they live. Your preferences — on surgery type, on where to be treated, on how to manage work and family — are part of the plan, not an afterthought.